a year of new treatments for endometrial cancer

Advancements in endometrial cancer treatments include checkpoint inhibitors, combination therapies, and antibody drug conjugates (ADCs). Approvals for GSK’s Jemperli and Merck’s Keytruda have expanded treatment options for patients. Also, the Lynparza-Imfinzi combo from AstraZeneca has gained approval from the EU for advanced cases. The development of ADCs, such as Enhertu, have shown promise in targeting tumor cells. The recent breakthroughs in therapeutic research could lead to more personalized treatment plans for patients.